Clinical trials: Digestive Disease
Metastatic Malignant Neoplasm
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NPX267 is an antibody drug targeting the inhibitory receptor for B7-H7 (HHLA2) which may control evasion of the immune response in tumors.
- Trial name
- NCT05958199
- Testing
- NPX267
- Where
- 7 sites in United States
- Volunteers
- 131 people
- Sponsor
- NextPoint Therapeutics, Inc.
Hepatocellular Carcinoma (HCC)
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
The purpose of this study is to measure the efficacy and safety of durvalumab intravenous (IV) solution plus bevacizumab IV solution after transarterial radioembolization (Yttrium 90 glass microspheres TARE) in participants with…
- Trial name
- EMERALD-Y90 (NCT06040099)
- Testing
- Durvalumab, Bevacizumab, Transarterial Radioembolization (TARE)
- Where
- 21 sites in United States
- Volunteers
- 58 people
- Sponsor
- AstraZeneca
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Refractory Metastatic Colorectal Cancer
Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients
This study is designed as an international, open-label, controlled two-arm, randomized phase III comparison study evaluating the efficacy and safety of trifluridine/tipiracil in combination with bevacizumab versus…
- Trial name
- SUNLIGHT (NCT04737187)
- Testing
- Trifluridine/Tipiracil, Bevacizumab
- Where
- 99 sites in United States, Austria and 12 more
- Volunteers
- 492 people
- Sponsor
- Taiho Oncology, Inc.
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Peginterferon alfa-2a plus…
- Trial name
- BASIS (NCT01754974)
- Testing
- Peginterferon Lambda-1a, Ribavirin, Peginterferon alfa-2a
- Where
- 16 sites in Czechia, Mexico and 1 more
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Neoplasm, Gastrointestinal
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]
The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed…
- Trial name
- NCT03329690
- Testing
- DS-8201a, Physician's Choice
- Where
- 66 sites in Japan, South Korea
- Volunteers
- 233 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Inflammatory Bowel Disease, Irritable Bowel Syndrome
BÜHLMANN fCAL™ ELISA - Aid in Differentiation of IBD From IBS
The purpose of this study is to confirm the sensitivity and specificity of the BÜHLMANN fCAL™ ELISA as an aid in diagnosis to differentiate between Inflammatory Bowel Disease (IBD; Crohn's Disease (CD), Ulcerative Colitis (UC)…
- Trial name
- NCT02351635
- Testing
- fecal calprotectin level
- Where
- 7 sites in United States
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- Bühlmann Laboratories AG
Biliary Tract Neoplasms, Neoplasms
Evolution® Biliary Stent System Clinical Study
The Evolution® Biliary Stent System Clinical Study is a clinical trial on a commercially available device to gather physician experience with the Cook Evolution® Biliary Stent System for the palliation of cancer in the biliary…
- Conditions
- Biliary Tract Neoplasms, Neoplasms, Gastrointestinal Diseases, Digestive System Diseases
- Trial name
- NCT01962168
- Testing
- Evolution® Biliary Stent - Uncovered
- Where
- 9 sites in United States, Canada
- Volunteers
- 113 people
- Sponsor
- Cook Group Incorporated
Colorectal Cancer, Adenoma
Comparing Detection of Standard Colonoscopy, CAD-EYE and Combined CAD-EYE and G-EYE® Aided Colonoscopy
The purpose of this study is to compare the additional diagnostic yield over Standard Colonoscopy (i.e., the adenoma miss-rate reduction) obtained by performing CADEYE and G-EYE® aided colonoscopy, vs.
- Trial name
- NCT05237310
- Testing
- Standard Colonoscopy, G-EYE Colonoscopy, CAD-EYE
- Where
- Germany
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Smart Medical Systems Ltd.
Crohn Disease, Complex Perianal Fistula
A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer
The main aim is to learn about the risk of cancer after treatment with darvadstrocel compared to other standards of care in people with Crohn's Disease (CD).
- Trial name
- NCT04971525
- Where
- 4 sites in France, Germany and 2 more
- Sponsor
- Takeda
Hepatocellular Carcinoma, Neoplasms
DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma
Evaluation of DC-CIK cells combined TACE treatment for HCC
- Conditions
- Hepatocellular Carcinoma, Neoplasms, Digestive System Neoplasms
- Trial name
- NCT02487017
- Testing
- Transcatheter Arterial Chemoembolization (TACE), DC-CIK
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shenzhen Hornetcorn Bio-technology Company, LTD
Crohn Disease
QBECO SSI for Clinical and Endoscopic Remission in Moderate to Severe Crohn's Disease
The QBECO-CD-02 trial in subjects with moderate to severe Crohn's disease (CD) is intended to build on past experience with QBECO SSI and further establish the safety and efficacy of QBECO SSI for the induction of clinical and/or…
- Trial name
- NCT03472690
- Testing
- QBECO-SSI
- Where
- 3 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Qu Biologics Inc.
Gastroesophageal Reflux Disease, Hiatal Hernia
Transoral Incisionless Fundoplication (TIF) Registry Study for Treatment of Gastroesophageal Reflux Disease (GERD)
The study objective is to evaluate the safety and efficacy of TIF among a broad range of GERD patients treated in routine clinical practice at multiple centers across the United States.
- Trial name
- NCT01118585
- Testing
- TIF Procedure
- Where
- 14 sites in United States
- Volunteers
- 278 people
- Sponsor
- EndoGastric Solutions
Gastric Cancer
Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy
Patients with early gastric cancer, who require therapeutic upper gastrointestinal endoscopy, such as endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD), will receive intragastric spraying of NPO-11 or…
- Trial name
- NCT01411176
- Testing
- Menthol
- Where
- Japan
- Volunteers
- 85 people
- Sponsor
- Nihon Pharmaceutical Co., Ltd
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
CRC (Colorectal Cancer)
PM8002 (BNT327) in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
PM8002 (BNT327) is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II trial to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in first line MSS or MSI-L/pMMR metastatic colorectal…
- Trial name
- NCT07133750
- Testing
- PM8002, Chemotherapy Regimen 1, Chemotherapy Regimen 2
- Where
- 11 sites in China
- Volunteers
- 100 people
- Sponsor
- Biotheus Inc.
Type 2 Diabetes Mellitus (T2DM), Non-Alcoholic Fatty Liver Disease (NAFLD)
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the…
- Trial name
- NCT06694935
- Testing
- QX1206
- Where
- Canada
- Volunteers
- 52 people
- Sponsor
- 1Globe Health Institute
Metastatic Pancreatic Cancer
Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
This clinical trial is an open label Phase II study of the combination of intravenously administered SGT-53 and gemcitabine/nab-paclitaxel in patients with metastatic pancreatic cancer.
- Trial name
- NCT02340117
- Testing
- SGT-53, nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- SynerGene Therapeutics, Inc.
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)
TARGET-NASH is a longitudinal observational cohort study of patients being managed for NASH and related conditions across the entire spectrum NAFLD in usual clinical practice.
- Trial name
- NCT02815891
- Where
- 72 sites in United States, Germany and 1 more
- Volunteers
- 7,330 people
- Sponsor
- Target PharmaSolutions, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.